|
|
|
|
|
|
|
|
|
|
"Patients with bulky, advanced ovarian cancer survived just as long whether treated with neoadjuvant chemotherapy and surgery or with primary surgery followed by adjuvant chemotherapy, investigators in a multinational trial reported."
"Subgroup analysis failed to identify any patient or tumor characteristics associated with better outcomes with one treatment strategy or the other. In both treatment groups, the success of cytoreductive surgery was the strongest predictor of survival."
Action Points
* Explain to interested patients that according to a recent randomized study, patients with bulky, advanced ovarian cancer survived just as long whether treated with neoadjuvant chemotherapy and surgery or with primary surgery followed by adjuvant chemotherapy
* Explain that both treatment strategies led to a median overall survival of about 30 months and median progression-free survival of 12 months.
Original Article
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer - NEJM
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.